News/ News/ R&D Ipsen tries again in Parkinson’s disease with $363m IRLAB deal Phil Taylor central nervous system, Ipsen, IRLAB, mesdopetam, neurology, Parkinson's disease 0 Comment French drugmaker Ipsen has made another foray into the Parkinson’s disease category, licensing rights to an oral dopamine Share X Ipsen tries again in Parkinson’s disease with $363m IRLAB deal https://pharmaphorum.com/news/ipsen-tries-again-in-parkinsons-disease-with-363m-irlab-deal/